Superantigen post-exposure therapy

A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ALUN JAMES CARTER, SARAH JOANNE CHRISTINE WHITFIELD
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	ALUN JAMES CARTER SARAH JOANNE CHRISTINE WHITFIELD
description	A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and the superantigen may be Staphylococcus Enterotoxin B (SEB). Also claimed is a method for monitoring responsiveness to post-exposure treatment of SAg-mediated disease with a pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor comprising measuring the concentration of biomarkers IFN-Î³ or IL-6 in pre-treatment and post-treatment samples and wherein a biomarker concentration lower in the post-treatment sample is a positive indicator of responsiveness to treatment.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_GB2525698A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>GB2525698A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_GB2525698A3</originalsourceid><addsrcrecordid>eNrjZFAKLi1ILUrMK8lMT81TKMgvLtFNrQBSpUWpCiUZQJmCSh4G1rTEnOJUXijNzSDv5hri7KGbWpAfn1pckJicmpdaEu_uZGRqZGpmaeFoTFgFAGHTJd8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Superantigen post-exposure therapy</title><source>esp@cenet</source><creator>ALUN JAMES CARTER ; SARAH JOANNE CHRISTINE WHITFIELD</creator><creatorcontrib>ALUN JAMES CARTER ; SARAH JOANNE CHRISTINE WHITFIELD</creatorcontrib><description>A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and the superantigen may be Staphylococcus Enterotoxin B (SEB). Also claimed is a method for monitoring responsiveness to post-exposure treatment of SAg-mediated disease with a pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor comprising measuring the concentration of biomarkers IFN-Î³ or IL-6 in pre-treatment and post-treatment samples and wherein a biomarker concentration lower in the post-treatment sample is a positive indicator of responsiveness to treatment.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151104&DB=EPODOC&CC=GB&NR=2525698A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151104&DB=EPODOC&CC=GB&NR=2525698A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ALUN JAMES CARTER</creatorcontrib><creatorcontrib>SARAH JOANNE CHRISTINE WHITFIELD</creatorcontrib><title>Superantigen post-exposure therapy</title><description>A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and the superantigen may be Staphylococcus Enterotoxin B (SEB). Also claimed is a method for monitoring responsiveness to post-exposure treatment of SAg-mediated disease with a pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor comprising measuring the concentration of biomarkers IFN-Î³ or IL-6 in pre-treatment and post-treatment samples and wherein a biomarker concentration lower in the post-treatment sample is a positive indicator of responsiveness to treatment.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFAKLi1ILUrMK8lMT81TKMgvLtFNrQBSpUWpCiUZQJmCSh4G1rTEnOJUXijNzSDv5hri7KGbWpAfn1pckJicmpdaEu_uZGRqZGpmaeFoTFgFAGHTJd8</recordid><startdate>20151104</startdate><enddate>20151104</enddate><creator>ALUN JAMES CARTER</creator><creator>SARAH JOANNE CHRISTINE WHITFIELD</creator><scope>EVB</scope></search><sort><creationdate>20151104</creationdate><title>Superantigen post-exposure therapy</title><author>ALUN JAMES CARTER ; SARAH JOANNE CHRISTINE WHITFIELD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_GB2525698A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2015</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>ALUN JAMES CARTER</creatorcontrib><creatorcontrib>SARAH JOANNE CHRISTINE WHITFIELD</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ALUN JAMES CARTER</au><au>SARAH JOANNE CHRISTINE WHITFIELD</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Superantigen post-exposure therapy</title><date>2015-11-04</date><risdate>2015</risdate><abstract>A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and the superantigen may be Staphylococcus Enterotoxin B (SEB). Also claimed is a method for monitoring responsiveness to post-exposure treatment of SAg-mediated disease with a pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor comprising measuring the concentration of biomarkers IFN-Î³ or IL-6 in pre-treatment and post-treatment samples and wherein a biomarker concentration lower in the post-treatment sample is a positive indicator of responsiveness to treatment.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_GB2525698A
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
title	Superantigen post-exposure therapy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A28%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ALUN%20JAMES%20CARTER&rft.date=2015-11-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EGB2525698A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true